VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a large increase in short interest during the month of July. As of July 31st, there was short interest totaling 570,467 shares, an increase of 1,070.7% from the July 15th total of 48,730 shares. Based on an average trading volume of 8,475,803 shares, the days-to-cover ratio is currently 0.1 days. Approximately 16.7% of the company’s stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP acquired a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs as of its most recent SEC filing. Hedge funds and other institutional investors own 8.23% of the company’s stock.

VivoSim Labs Trading Down 3.2%

Shares of VivoSim Labs stock traded down $0.01 during trading hours on Tuesday, reaching $0.35. 3,220,143 shares of the company’s stock were exchanged, compared to its average volume of 16,634,510. The company has a 50 day moving average of $0.81 and a two-hundred day moving average of $1.39. VivoSim Labs has a fifty-two week low of $0.31 and a fifty-two week high of $5.30.

VivoSim Labs (NASDAQ:VIVS) last released its earnings results on Tuesday, July 14th. The company reported ($2.21) earnings per share (EPS) for the quarter. VivoSim Labs had a negative net margin of 10,567.17% and a negative return on equity of 277.62%. The company had revenue of $0.04 million during the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.